Elena M. – Liver Failure & Transplant After Oxbryta

Background

Elena M., a 32-year-old nurse from Miami, began Oxbryta. Within 11 months, routine labs showed alarming liver enzyme levels (ALT 1,200 U/L). Despite discontinuation, she progressed to fulminant hepatic failure requiring emergency transplant.

Medical Impact

• Transplant Timeline:
  • Spent 47 days on transplant waiting list
  • Living donor surgery (sister donated 60% of liver)
• Life-Altering Consequences:
  • Forced early retirement from nursing career
  • Lifelong immunosuppressant regimen ($12K/month meds)
  • PTSD from near-death experience

Initial Challenges

1. Transplant center initially blamed "undiagnosed pre-existing condition"
2. Pfizer argued liver injury was "idiosyncratic reaction"
3. Disability claims repeatedly denied

How Injurease Helped

• Retained hepatologist who proved Oxbryta’s mechanism caused mitochondrial toxicity
• Obtained FDA adverse event reports showing 14 similar liver failure cases
• Structured settlement to ensure lifetime medical coverage
• Connected Elena with transplant patient advocacy groups

Legal Approach

Key evidence included:

• Pfizer’s 2021 internal memo flagging hepatotoxicity signals
• Clinical trial data showing ALT elevations in 18% of participants
• Whistleblower testimony about suppressed safety concerns

Outcome

• $3.75M structured settlement with:
  • $2M upfront for debts/home modifications
  • $1.75M annuity for lifelong care
• Non-monetary wins:
  • Pfizer agreed to update global pharmacovigilance protocols
  • Case cited in JAMA Hepatology safety review

Elena’s Reflection:
"As a nurse, I trusted the system. Now I know how easily Big Pharma can betray that trust. Injurease gave me the strength to turn my tragedy into protection for others."

[fluentform_modal form_id="12" btn_text="Click to Start Case Evaluation"]